Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2

Journal of Nuclear Medicine

Volumn 45, Issue 5, 2004, Pages 867-877

  Cheung, Nai Kong V ^a   Modak, Shakeel ^a   Lin, Yukang ^b   Guo, Hongfen ^a   Zanzonico, Pat ^a   Chung, John ^a   Zuo, Yuting ^b   Sanderson, James ^b   Wilbert, Sibylle ^b   Theodore, Louis J ^b   Axworthy, Donald B ^b   Larson, Steven M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Poniard Pharmaceuticals Inc   (United States)

Author keywords

Biodistribution; Dosimetry; Multistep targeting; ScFv streptavidin; Single chain variable fragment

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; COMPLEMENTARY DNA; GANGLIOSIDE GD2; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; STREPTAVIDIN; GANGLIOSIDE; INDIUM; SIALOGANGLIOSIDES;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOSIMETRY; ESCHERICHIA COLI; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RADIOACTIVITY; SCINTIGRAPHY; ANIMAL; C57BL MOUSE; CELL CULTURE; EXPERIMENTAL NEOPLASM; HUMAN; METABOLISM; MOUSE MUTANT; NUDE MOUSE;

ANIMALS; GANGLIOSIDES; HUMANS; INDIUM RADIOISOTOPES; MICE; MICE, INBRED C57BL; MICE, NUDE; MICE, SCID; NEOPLASMS, EXPERIMENTAL; STREPTAVIDIN; TUMOR CELLS, CULTURED;

EID: 2642527143     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Rodden FA, Wiegandt H, Bauer BL. Gangliosides: the relevance of current research to neurosurgery. J Neurosurg. 1991;74:606-619.
2. Larson SM, Divgi C, Sgouros G, Cheung NKC, Scheinberg DA. Monoclonal antibodies: basic principles - adioisotope conjugates. In: DeVita VT, Hellman S, Rosenberg SA, eds. Biologic Therapy of Cancer: Principles and Practice. Philadelphia, PA: JB Lippincott; 2000:396-412.
3. Cheung NK, Saarinen U, Neely J, Landmeier B, Donovan D, Coccia P. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res. 1985;45:2642-2649.
4. Honsik CJ, Jung G, Reisfeld RA. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. Proc Natl Acad Sci USA. 1986;83:7893-7897.
5. Cheung NK, Kushner BH, Kramer K. Monoclonal antibody-based therapy of neuroblastoma. Hematol Oncol Clin North Am. 2001;15:853-866.
6. Huston JS, Levinson D, Mudgett-Hunter M, et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA. 1988;85:5879-5883.
7. Bird RE, Hardman KD, Jacobson JW, et al. Single-chain antigen-binding proteins. Science. 1988;242:423-426.
8. Kipriyanov SM, Bretling F, Little M, Dubel S. Single-chain antibody streptavidin fusions: tetrameric bifunctional scFv-complexes with biotin binding activity and enhanced affinity to antigen. Hum Antibodies Hybridomas. 1995;6:93-101.
9. Zhang M, Zhang Z, Garmestani K, et al. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci USA. 2003;100:1891-1895.
10. Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med. 1987;28:1294-1302.
11. Paganelli G, Malcovati M, Fazio F. Monoclonal antibody pretargetting techniques for tumour localization: the avidin-biotin system: International Workshop on Techniques for Amplification of Tumour Targetting. Nucl Med Commun. 1991;12:211-234.
12. Goodwin DA, Meares CF. Pretargeting: general principles - October 10-12, 1996. Cancer. 1997;80(12 suppl):2675-2680.
13. Theodore LJ, Fritzberg AR, Schultz JE, Axworthy DB. Evolution of a pretarget radioimmunotherapeutic regimen. In: Abrams PG, Fritzberg AR, eds. Radioimmunotherapy of Cancer. New York, NY: Marcel Dekker; 2000:195-221.
14. Goldenberg DM. Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother. 2003;52:281-296.
15. Cheung NK, Guo HF, Modak S, Cheung IY. Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapy. Hybrid Hybridomics. 2003;22:209-218.
16. Guo HF, Rivlin K, Dubel S, Cheung NKV. Recombinant anti-ganglioside GD2 scFv-streptavidin fusion protein for tumor pretargeting [abstract]. Proc Am Assoc Cancer Res. 1996;37:469.
17. Schultz J, Lin Y, Sanderson J, et al. A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. Cancer Res. 2000;60:6663-6669.
18. Cheung NK, Guo HF, Modak S, Cheung IY. Anti-idiotypic antibody as the surrogate antigen for cloning scFv and its fusion proteins. Hybrid Hybridomics. 2002;21:433-443.
19. Theodore L, Axworthy D, inventors; NeoRx Corporation, assignee. Cluster clearing agents. US patent 6 172 045. January 9, 2001.
20. Axworthy DB, Reno JM, Hylarides MD, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA. 2000;97:1802-1807.
21. Cheung NK, Landmeier B, Neely J, et al. Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice. J Natl Cancer Inst. 1986;77:739-745.
22. Boston RC, Weiss M, Shahn E. Conversational SAAM: an interactive program for kinetic analysis of biological systems. Comput Programs Biomed. 1981;13:1111-1119.
23. Zanzonico P, Poston JW. Computational methods in internal radiation dosimetry. In: Zaidi H, Sgouros G, eds. Monte Carlo Calculations in Nuclear Medicine: Therapeutic Applications. Bristol, U.K.: IOP Publishing Ltd.; 2002:84-108.
24. Stabin MG, Konijnenberg MW. Re-evaluation of absorbed fractions for photons and electrons in spheres of various sizes. J Nucl Med. 2000;41:149-160.
25. Kolbert KS, Watson T, Matei C, Xu S, Koutcher JA, Sgouros G. Murine S factors for liver, spleen, and kidney. J Nucl Med. 2003;44:784-791.
26. Cheung NK, Neely JE, Landmeier B, Nelson D, Miraldi F. Targeting of ganglioside GD2 monoclonal antibody to neuroblastoma. J Nucl Med. 1987;28:1577-1583.
27. Ugur O, Kostakoglu L, Hui ET, et al. Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: dosimetry calculations incorporating cross-organ beta doses. Nucl Med Biol. 1996;23:1-8.
28. Ganea D, Delgado M. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. Crit Rev Oral Biol Med. 2002;13:229-237.
29. 90Y-DOTA-biotin. J Nucl Med. 2000;41:131-140.
30. Knox SJ, Goris ML, Tempero M, et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res. 2000;6:406-414.
31. Press OW, Corcoran M, Subbiah K, et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood. 2001;98:2535-2543.
32. Zhang M, Yao Z, Garmestani K, et al. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. Blood. 2002;100:208-216.
33. Weiden PL, Breitz HB, Press O, et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. Cancer Biother Radiopharm. 2000;15:15-29.
34. 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. Cancer Biother Radiopharm. 2001;16:227-235.
35. DeNardo SJ, DeNardo GL, DeNardo DG, et al. Antibody phage libraries for the next generation of tumor targeting radioimmunotherapeutics. Clin Cancer Res. 1999;5(10 suppl):3213s-3218s.
36. Boerman OC, Kranenborg MH, Oosterwijk E, et al. Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate. Cancer Res. 1999;59:4400-4405.
37. Onda M, Nagata S, Tsutsumi Y, et al. Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity. Cancer Res. 2001;61:5070-5077.
38. Chinol M, Casalini P, Maggiolo M, et al. Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity. Br J Cancer. 1998;78:189-197.